Mechanisms of cardiotoxicity associated with ErbB2 inhibitors

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 595-602

  Fedele, Carmine ^a   Riccio, Gennaro ^a   Malara, Angela Eliana ^a   D'alessio, Giuseppe ^a   De Lorenzo, Claudia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer therapy; Cardiotoxicity; ErbB2 Her2; Herceptin trastuzumab; Lapatinib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LAPATINIB; NEU DIFFERENTIATION FACTOR; NEUREGULIN 1 BETA; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CELL GROWTH; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MYOBLASTS, CARDIAC; MYOCYTES, CARDIAC; PROTEIN BINDING; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84868207923     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2103-8     Document Type: Article

References (29)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science 235(4785):177-182
2. Baselga J, Albanell J, Molina MA, Arribas J (2001) Mechanism of action of trastuzumab and scientific update. Semin Oncol 28:4-11
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
4. Sparano JA (2001) Cardiac toxicity of trastuzumab (herceptin): implications for the design of adjuvant trials. Semin Oncol 28:20-27. doi:10.1053/sonc.2001.22813
5. Chien KR (2000) Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 27:9-14 (discussion 92-100)
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459-465. doi:10.1038/nm0502-459
7. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344. doi:10.1038/nrc2106
8. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543. doi:10.1200/JCO. 2005.03.184
9. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313. doi:10.1200/JCO.2005.16.584
10. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proc 83:679-686
11. Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C (2011) Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat. doi:10.1007/s10549-011-1783-9
12. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G (2002) Anew human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8:1710-1719
13. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91:1200-1204. doi:10.1038/sj.bjc.6602110
14. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26:1890-1895. doi:10.1093/carcin/bgi146
15. De Lorenzo C, Troise F, Cafaro V, D'Alessio G (2007) Combinatorial experimental protocols for erbicin-derived immunoagents and herceptin. Br J Cancer 97:1354-1360. doi:10.1038/sj.bjc.6604022
16. Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C (2011) A novel ErbB2 epitope targeted by human antitumor immunoagents. FEBS J 278:1156-1166. doi:10.1111/j.1742-4658. 2011. 08041.x
17. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D'Alessio G, De Lorenzo C (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23:3171-3178. doi:10.1096/fj.09-131383
18. Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE (1997) Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 57:3804-3811
19. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/Neu gene product. Cancer Res 50:1550-1558
20. Kuramochi Y, Guo X, Sawyer DB (2006) Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41:228-235
21. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G (1995) Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378:390-394
22. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398
23. Meyer D, Birchmeier C (1995) Multiple essential functions of neuregulin in development. Nature 378:386-390
24. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261-10269
25. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467
26. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
27. Fuller SJ, Sivarajah K, Sugden PH (2008) ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 44:831-854
28. Bersell K, Arab S, Haring B, Kuhn B (2009) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138:257-270
29. De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106:35-46